Evofem Competitors

Summary

EVFMDDelisted Stock

0.64 0.05 8.47%

Evofem Biosciences competes with Gentex, Magna International, PACCAR, Aeye, and BorgWarner; as well as few others. Analyzing Evofem Biosciences competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Evofem Biosciences to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in population.

You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Evofem Biosciences competition on your existing holdings.

Specify up to 10 symbols:

Evofem Biosciences Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Evofem Biosciences and its competitors represents the degree of relationship between the price movements of corresponding otcs. A correlation of about +1.0 implies that the price of Evofem and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Evofem Biosciences does not affect the price movement of the other competitor.

	GNTX	MGA	PCAR	LIDR	BWA	CNLFF	PLTK
GNTX		0.48	0.26	-0.05	0.17	0.01	0.36	GNTX
MGA	0.48		0.8	-0.3	0.39	0.45	0.83	MGA
PCAR	0.26	0.8		-0.26	0.39	0.79	0.79	PCAR
LIDR	-0.05	-0.3	-0.26		0.24	-0.06	-0.52	LIDR
BWA	0.17	0.39	0.39	0.24		0.46	0.32	BWA
CNLFF	0.01	0.45	0.79	-0.06	0.46		0.47	CNLFF
PLTK	0.36	0.83	0.79	-0.52	0.32	0.47		PLTK
	GNTX	MGA	PCAR	LIDR	BWA	CNLFF	PLTK

Click cells to compare fundamentals

Check Volatility

Backtest Portfolio

High positive correlations

PLTK	+ 0.83	MGA
PCAR	+ 0.8	MGA
CNLFF	+ 0.79	PCAR
PLTK	+ 0.79	PCAR
MGA	+ 0.48	GNTX
PLTK	+ 0.47	CNLFF

High negative correlations

PLTK	- 0.52	LIDR
LIDR	- 0.3	MGA
LIDR	- 0.26	PCAR
CNLFF	- 0.06	LIDR
LIDR	- 0.05	GNTX

Risk-Adjusted Indicators

There is a big difference between Evofem OTC Stock performing well and Evofem Biosciences OTC Stock doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Evofem Biosciences' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.

	Mean Deviation	Jensen Alpha	Sortino Ratio	Treynor Ratio	Semi Deviation	Expected Shortfall	Potential Upside	Value @Risk	Maximum Drawdown
GNTX	1.13	(0.10)	(0.09)	(0.01)	1.43	(1.17)	2.24	(2.36)	7.93
MGA	1.62	(0.02)	0.01	0.11	2.26	(1.52)	3.06	(3.95)	11.56
PCAR	1.26	0.14	0.14	0.23	1.14	(1.51)	3.32	(2.43)	10.18
LIDR	3.16	(0.26)	0.00	(0.08)	0.00	0.00	7.55	(5.74)	17.33
BWA	1.33	(0.11)	(0.05)	0.03	1.70	(1.34)	2.84	(2.87)	7.85
CNLFF	0.05	0.02	0.00	(1.28)	0.00	0.00	0.00	0.00	1.03
PLTK	1.18	0.07	0.03	0.21	1.24	(1.32)	2.33	(2.19)	7.19

Unable to evaluate fundamental data of Evofem Biosciences at this time. Please try again later

All Fundamental Data

Evofem Biosciences Competitive Analysis

The better you understand Evofem Biosciences competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Evofem Biosciences' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Evofem Biosciences' competition over several years is one of the best ways to analyze its investment potential.

Better Than Average

Worse Than Peers

View Performance Chart

	EVFMD	GNTX	MGA	PCAR	LIDR	BWA	CNLFF	PLTK
	8.47 0.64 Evofem	0.03 30.56 Gentex	0.42 45.14 Magna	0.71 117.00 PACCAR	5.61 1.13 Aeye	0.12 34.32 BorgWarner	0.00 2.97 Canlan	1.08 8.42 Playtika
Market Volatility (90 Days Market Risk)	Unknown risk	Very steady	Very steady	Very steady	Extremely Dangerous	Very steady	Very steady	Not too volatile
Market Performance (90 Days Performance)	Very Weak	Very Weak	Modest	Good	Very Weak	Insignificant	Good	Good
Odds of Financial Distress (Probability Of Bankruptcy)	Unknown	Very Low	Very Low	Very Low	Very High	Low	Average	Low
Current Valuation (Equity Enterprise Value)	Over Valued	Under Valued	Under Valued	Over Valued	Over Valued	Under Valued	Fairly Valued	Under Valued
Buy or Sell Advice (Average Analysts Consensus)	Not Available	Buy	Buy	Buy	Hold	Strong Buy	Not Available	Buy
Trade Advice (90 Days Macroaxis Advice)	Not Rated	Strong Hold	Cautious Hold	Strong Buy	Cautious Hold	Hold	Cautious Hold	Strong Hold
Current Ratio		3.47 X	1.30 X	4.31 X	8.31 X	1.72 X	0.63 X	2.41 X
Net Asset		2.61 B	32.26 B	40.82 B	54.32 M	14.45 B	116.61 M	3.17 B
Profit Margin		0.18 %	0.03 %	0.14 %	N/A	0.06 %	0.07 %	0.09 %
EBITDA		589.05 M	3.66 B	5.41 B	(85.52 M)	1.16 B	7.88 M	703.6 M
Operating Margin		0.21 %	0.05 %	0.14 %	(258.00) %	0.08 %	0.03 %	0.20 %
Current Valuation		6.75 B	19.41 B	67.07 B	(8.63 M)	10.24 B	64.71 M	4.4 B
Price To Book		2.88 X	1.05 X	3.26 X	0.66 X	1.22 X	1.36 X	N/A
Retained Earnings		1.34 B	9.26 B	15.78 B	(337.63 M)	6.15 B	N/A	(907.6 M)
Current Asset		618.99 M	11.14 B	5.39 B	N/A	838.3 M	N/A	N/A
Five Year Return		1.71 %	2.57 %	1.60 %	N/A	1.67 %	N/A	N/A
Beta		0.91	1.6	0.89	2.95	1.19	1.06	0.84
Number Of Employees		6.25 K	162 K	32.4 K	60	39.9 K	1.1 K	3.6 K
Shares Outstanding		227.43 M	287.34 M	524.3 M	9.13 M	218.7 M	13.34 M	372.71 M
Cash Flow From Operations		537.25 M	3.15 B	4.19 B	(50.73 M)	1.4 B	12.14 M	515.6 M
Annual Yield		0.02 %	0.04 %	0.01 %	N/A	0.01 %	N/A	0.05 %
Total Debt		3.57 M	7.22 B	14.38 B	17.27 M	3.93 B	39.36 M	2.52 B
Return On Equity		0.19	0.0949	0.27	-1.46	0.16	0.12	N/A
Z Score		N/A	N/A	N/A	N/A	N/A	0.6	N/A
Return On Asset		0.12	0.0393	0.0846	-0.42	0.0527	0.0096	0.0986
Number Of Shares Shorted		5.94 M	7.92 M	12.45 M	262.39 K	7.47 M	N/A	4.06 M
Book Value Per Share		10.63 X	42.72 X	35.60 X	4.60 X	28.15 X	3.37 X	(0.26) X
Current Liabilities		58.09 M	7.28 B	2.92 B	N/A	484 M	N/A	N/A
Total Asset		2.61 B	32.26 B	40.82 B	54.32 M	14.45 B	116.61 M	3.17 B
Debt To Equity		0 %	0.45 %	0.81 %	0.15 %	0.59 %	1.68 %	N/A
Short Ratio		3.82 X	8.44 X	4.43 X	1.97 X	3.73 X	N/A	7.53 X
Target Price		34.5	49.8	113.99	1.0	41.45	N/A	9.8
Last Dividend Paid		0.48	1.9	1.14	N/A	0.44	0.03	0.3
Shares Owned By Institutions		97.85 %	76.63 %	72.17 %	21.70 %	99.34 %	N/A	15.96 %
Market Capitalization		6.95 B	12.97 B	61.34 B	9.77 M	7.51 B	39.65 M	3.1 B
Price To Earning		19.08 X	24.46 X	14.12 X	N/A	17.95 X	N/A	12.93 X
Price To Earnings To Growth		1.63 X	0.42 X	1.18 X	N/A	1.36 X	N/A	17.80 X
Price To Sales		2.94 X	0.30 X	1.76 X	31.63 X	0.53 X	0.56 X	1.22 X
Net Income		428.4 M	1.29 B	4.6 B	(87.13 M)	702 M	(1.09 M)	235 M
Earnings Per Share		1.89 X	3.75 X	8.93 X	(8.51) X	4.04 X	0.18 X	0.58 X
Shares Owned By Insiders		0.24 %	6.10 %	1.86 %	8.59 %	0.66 %	93.36 %	85.68 %
Revenue		2.3 B	42.8 B	35.13 B	1.46 M	14.2 B	40.39 M	2.57 B
Working Capital		726.13 M	803 M	19.22 B	29.73 M	2.45 B	N/A	811.5 M
Cash And Equivalents		281.36 M	1.23 B	4.76 B	125.76 M	1.24 B	4.59 M	1.25 B
Cash Per Share		1.20 X	5.76 X	13.70 X	0.79 X	5.27 X	0.34 X	3.03 X
Gross Profit		609.81 M	4.65 B	4.61 B	(5.08 M)	3.1 B	32.25 M	1.88 B
Day Typical Price	0.64	30.68	45.0	116.89	1.11	34.31	2.97	8.41
Accumulation Distribution	0.16	7221.62	16515.44	11472.91	3942.87	22821.76	N/A	5106.0
Market Facilitation Index	0.11	0.0	0.0	0.0	0.0	0.0	N/A	0.0
Daily Balance Of Power	0.4545	(0.03)	0.2346	0.6508	0.6667	0.0526	0.0	0.5
Period Momentum Indicator	0.05	(0.01)	0.19	0.82	0.06	0.04	N/A	0.09
Rate Of Daily Change	1.08	1.0	1.0	1.01	1.06	1.0	1.0	1.01
Day Median Price	0.65	30.74	44.93	116.83	1.1	34.3	2.97	8.4
Price Action Indicator	0.02	(0.18)	0.31	0.58	0.065	0.04	N/A	0.065
Relative Strength Index	33.28	48.43	60.2	67.68	39.12	46.13	100.0	74.05
Coefficient Of Variation	(808.20)	25067.29	1420.17	514.23	(4,595)	3494.05	582.23	790.99
Mean Deviation	7.94	1.13	1.62	1.26	3.16	1.33	0.0501	1.18
Jensen Alpha	(0.97)	(0.1)	(0.02)	0.1449	(0.26)	(0.11)	0.0174	0.0677
Total Risk Alpha	(3.27)	(0.25)	(0.22)	0.0385	(0.80)	(0.25)	(0.01)	(0.07)
Sortino Ratio	N/A	(0.09)	0.0075	0.1441	N/A	(0.05)	N/A	0.0333
Downside Variance	N/A	2.18	6.53	2.02	N/A	3.15	N/A	2.12
Standard Deviation	11.2	1.49	2.23	1.76	4.2	1.74	0.1504	1.47
Kurtosis	1.74	1.92	0.8249	3.34	1.06	1.0E-4	35.96	0.0319
Potential Upside	17.32	2.24	3.06	3.32	7.55	2.84	N/A	2.33
Treynor Ratio	0.4223	(0.01)	0.1134	0.2261	(0.08)	0.0331	(1.28)	0.2073
Maximum Drawdown	52.56	7.93	11.56	10.18	17.33	7.85	1.03	7.19
Variance	125.5	2.22	4.95	3.1	17.64	3.01	0.0226	2.17
Market Risk Adjusted Performance	0.4323	0.0044	0.1234	0.2361	(0.07)	0.0431	(1.27)	0.2173
Risk Adjusted Performance	(0.09)	0.0079	0.0604	0.1543	(0.01)	0.0275	0.0905	0.1015
Skewness	(0.15)	0.3476	(0.32)	0.8117	0.7561	(0.02)	5.97	0.0462
Semi Deviation	N/A	1.43	2.26	1.14	N/A	1.7	N/A	1.24
Information Ratio	(0.14)	(0.09)	0.0086	0.1164	(0.05)	(0.05)	(0.74)	0.033
Value At Risk	(19.57)	(2.36)	(3.95)	(2.43)	(5.74)	(2.87)	N/A	(2.19)
Expected Short fall	N/A	(1.17)	(1.52)	(1.51)	N/A	(1.34)	N/A	(1.32)
Downside Deviation	N/A	1.48	2.56	1.42	N/A	1.77	N/A	1.46
Semi Variance	N/A	2.04	5.11	1.29	N/A	2.9	N/A	1.54

Evofem Biosciences Competition Performance Charts

Five steps to successful analysis of Evofem Biosciences Competition

Evofem Biosciences' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Evofem Biosciences in relation to its competition. Evofem Biosciences' competition analysis typically involves several steps, including:

Identifying the key players in the market: This involves identifying the major competitors of Evofem Biosciences in the market, both direct and indirect, as well as new entrants and disruptive technologies.
Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Evofem Biosciences' competitive landscape.
Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Evofem Biosciences, and developing a strategy to address them.
Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.

Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Evofem Biosciences position

In addition to having Evofem Biosciences in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Global Macro ETFs Thematic Idea Now

Global Macro ETFs

ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Global Macro ETFs theme has 26 constituents at this time.

You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Global Macro ETFs Theme or any other thematic opportunities.

View All Next

Launch

Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in population.

You can also try the CEOs Directory module to screen CEOs from public companies around the world.

Other Consideration for investing in Evofem OTC Stock

If you are still planning to invest in Evofem Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Evofem Biosciences' history and understand the potential risks before investing.

	Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
	Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
	Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities
	Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges
	Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
	Volatility Analysis Get historical volatility and risk analysis based on latest market data

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC